Pulmonary Microbiota and ARDS Mortality

Study Overview
=================
Brief Summary
-----------------
Acute respiratory distress syndrome (ARDS) is due to diffuse and severe lung inflammation. Despite intensive research, few therapeutics have emerged and treatment is still mostly symptomatic. As lung microbiota seems to be associated with lung inflammation in numerous chronic respiratory diseases, this study aims to analyse the correlation between lung microbiota and mortality.

Detailed Description
-----------------
ARDS is caused by diffuse intense lun inflammation. Its mortality rate is still about 40%. Despite decades of research, few therapeutics have emerged. Treatment is based on the treatment of ARDS cause, if possible and on protective ventilation, curare use and prone position. For more severe cases, nitric monoxide inhalation and extra-corporeal membrane oxygenation can be considered. Nevertheless, no treatment specifically addresses lung inflammation. Lung microbiota has been shown to be associated with lung inflammation in asthma, chronic obstructive disease and cystic fibrosis. Lung microbiota also plays a role in lung immunity. Regarding specifically ARDS, one study correlated lung microbiota with the occurrence of non-infectious ARDS in trauma patients. Thi study therefore aims to analyse the correlation between lung microbiota at admission to ICU for ARDS with mortality.

Official Title
-----------------
Association of Lung Microbiota With Intensive Care Unit Mortality in ARDS Patients: MicrA Study

Conditions
-----------------
Acute Respiratory Distress Syndrome

Intervention / Treatment
-----------------
* Other: tracheal aspirate during routine care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient above 18 year-old admitted to intensive care unit ARDS according to Berlin criteria Needing oro-tracheal intubation for mechanical ventilation Within the first 48 hours of ARDS evolution Exclusion Criteria: Guardianship or curatorship Prisoners No health insurance No legal representative

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: tracheal aspirate during routine care|tracheal aspirate during routine care|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| lung bacteriobiota and ICU mortality | Comparison of lung bacteriobiota alpha diversity between ARDS ICU survivors and non-survivors | at admission | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| lung mycobiota and ICU mortality | Comparison of lung mycobiota alpha diversity between ARDS ICU survivors and non-survivors | at admission | 
| lung mycobiota and 1-month mortality | Comparison of lung mycobiota alpha diversity between ARDS 1-month survivors and non-survivors | microbiota : at admission, mortality: 1 month after inclusion | 
| lung bacteriobiota and ICU mortality | Analysis of lung bacteriobiota beta diversity between ARDS ICU survivors and non-survivors | at admission | 
| lung bacteriobiota and 1-month mortality | Analysis of lung bacteriobiota beta diversity between ARDS 1-month survivors and non-survivors | microbiota : at admission, mortality: 1 month after inclusion | 
| lung mycobiota and ICU mortality | Analysis of lung mycobiota beta diversity between ARDS ICU survivors and non-survivors | at admission | 
| lung mycobiota and 1-month mortality | Analysis of lung mycobiota beta diversity between ARDS 1-month survivors and non-survivors | microbiota : at admission, mortality: 1 month after inclusion | 
| bacteria and ICU mortality | Association of bacteria with ARDS ICU mortality by LefSe method | at admission | 
| bacteria and 1-month mortality | Association of bacteria with ARDS 1-month mortality by LefSe method | microbiota : at admission, mortality: 1 month after inclusion | 
| fungi and ICU mortality | Association of fungi with ARDS ICU mortality by LefSe method | at admission | 
| fungi and 1-month mortality | Association of fungi with ARDS 1-month mortality by LefSe method | microbiota : at admission, mortality: 1 month after inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acute respiratory distress syndrome, microbiota, intensive care unit